ICON plc: ICON Reports Second Quarter 2026 Results
ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.
How this was made
The 30-second read
Why it matters
Key decision points for traders are the reaffirmed 2026 revenue and adjusted diluted EPS ranges, the strength in net business wins and backlog, and the mixed profitability picture (adjusted EBITDA down year over year, GAAP EPS down).
Market read
The combination of higher net business wins and backlog with reaffirmed guidance is supportive, but the adjusted EBITDA decline and GAAP EPS drop add caution for near-term valuation and margin expectations.
What to watch
The article highlights pass-through variability as a driver of second-half performance; traders may focus on how that affects cash conversion and adjusted EBITDA rather than bookings alone.
Background
ICON plc, a clinical research organization, released its Q2 2026 financial results and reiterated its 2026 full-year guidance ranges.
Ticker impact
ICON reported Q2 2026 revenue of $2,063.5m, net business wins of $3,120m, and reaffirmed 2026 guidance for revenue and adjusted EPS.
Likely modest positive reaction versus peers if investors focus on backlog and book-to-bill, but tempered by the adjusted EBITDA decline and GAAP EPS drop.
The article provides multiple primary datapoints: revenue, adjusted EBITDA, GAAP and adjusted EPS, net bookings/book-to-bill, backlog, and explicit reaffirmed 2026 guidance ranges. The direction is mixed (earnings down on GAAP and adjusted EBITDA down) but bookings and backlog are up, which typically supports sentiment for CRO demand visibility.
Market effects
CRO demand visibility signal via net business wins, book-to-bill, and backlog can influence read-across sentiment for clinical research outsourcing peers.
Limited direct regional impact; ICON’s results are global CRO operations but may affect US-listed CRO sentiment broadly.
Backlog and bookings metrics can be used by global CRO investors to benchmark pipeline conversion and pass-through dynamics.
Counterpoint
Investors may discount bookings strength if adjusted EBITDA and GAAP earnings deteriorated, implying margin headwinds from pass-through activity or cost structure.
Key entities
- companyICON plc
NASDAQ-listed CRO reporting Q2 2026 results, bookings/backlog metrics, and reaffirmed 2026 guidance.
- personBarry Balfe
ICON CEO commenting on Q2 progress, cost management, and pass-through headwinds.
